CORRELATION OF SERUM PROGESTAGEN-ASSOCIATED ENDOMETRIAL PROTEIN-LEVELS WITH ENDOMETRIAL BIOPSIES SERUM STEROID-LEVELS AND THERAPY FOR LUTEAL PHASE DEFECTS

被引：12

作者：

CHECK, JH ^{[1
]}

NOWROOZI, K ^{[1
]}

CHECK, ML ^{[1
]}

VETTER, B ^{[1
]}

机构：

[1] UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSTON MED SCH,CAMDEN,NJ

来源：

HUMAN REPRODUCTION | 1991年 / 6卷 / 04期

关键词：

ENDOMETRIAL BIOPSIES; LUTEAL PHASE DEFECTS; SERUM PEP; SERUM STEROID LEVELS;

D O I：

10.1093/oxfordjournals.humrep.a137369

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The progestagen-associated endometrial protein (PEP) level rises from the early to the late luteal phase. A study was performed in infertile women where late luteal phase endometrial biopsies and serum PEP levels were obtained. The objective of the study was to evaluate the correlation between the PEP levels and the endometrial biopsies and to determine if subnormal PEP levels could be improved by the same therapies used to correct endometrial defects. There was a poor correlation between PEP levels and endometrial biopsies (r = 0.17). Similarly, there was no significant correlation between PEP levels and levels of the following hormones: mid- and late-luteal phase progesterone (P) (r = 0.186 and 0.282 respectively), mid-luteal phase 17-hydroxyprogesterone (17-OHP) (r = 0.139) and mid-luteal phase oestradiol (r = 0.135). Furthermore, there was no correlation between PEP levels and the dosage of progesterone used in therapy (r = 0.07). There were no statistically significant differences in PEP values (U/ml) depending on whether any fertility drug was taken. Thus our data suggest that progesterone may only have a permissive role, with some other factor(s) controlling the actual rise and fall of PEP.

引用

页码：511 / 514

页数：4

共 19 条

[1]

Bell S.C., Secretory endometrial/decidual proteins and their function in early pregnancy, J. Reprod. Fertil, 36, pp. 109-125, (1988)

[2]

Bell S.C., Hales M.W., Patel S., Kruman P.H., Drife J.O., Protein synthesis and secretion by the human endometrium and decidua during early pregnancy, Br. J. Obstet. Gynaecol, 92, pp. 793-803, (1985)

[3]

Bell S.C., Patel S.R., Kirwan P.H., Drife J.O., Protein synthesis and secretion by the human endometrium during the menstrual cycle and the effect of progesterone in vitro, J. Reprod. Fenil, 77, pp. 221-231, (1986)

[4]

Bell S.C., Jackson J., Dore-Green F., Kirwan P.H., Drife J.O., Development and validation of a radioimmunoassay for human secretory ‘pregnancy associated endometrial α2 globulin’ (α2-PEG) and detection in serum during pregnancy, Hum. Reprod, 2, pp. 389-397, (1987)

[5]

Bolton A., Clough K., Stoker R., Pockley A., Mowles E., Westwood O., Chapman M., Identification of placental protein 14 as an immunosuppressive factor in human reproduction, Lancet, 1, pp. 593-595, (1987)

[6]

Check J.H., Adelson H., The efficacy of progesterone in achieving successful pregnancy: II. In women with pure luteal phase defects, Int. J. Fertil, 32, pp. 139-141, (1987)

[7]

Check J.H., Nowroozi K., Wu C., Adelson H., Lauer C., Ovulation inducing drugs versus progesterone therapy for infertility in patients with luteal phase defects, Int. J. Fertil, 33, pp. 252-256, (1988)

[8]

Check J.H., Chase J., Nowroozi K., Wu C., Chem R., Clinical evaluation of the Pipelle endometrial suction curette for timed endometrial biopsies, J. Reprod. Med, 34, pp. 218-220, (1989)

[9]

Check J.H., Wu C., Adelson H., Bromocriptine versus progesterone therapy for infertility related to luteal phase defects in hyperprolactinemic patients, Int. J. Fertil, 34, pp. 209-214, (1989)

[10]

Critchley H.O.D., Chard T., Lieberman B.A., Buckley C.H., The ovary is essential for PP14 production in early pregnancy, The Viith World Congress on Human Reproduction, (1990)

← 1 2 →